|
|
Article: Micromet Establishes New Scientific Advisory Board for Its BiTE Antibody Technology with Leading Experts in the Fields of Oncology, Immunotherapy and Drug Development.
- Article from:
- PR Newswire
- Article date:
- March 25, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BETHESDA, Md., March 25 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today named five leading oncology and immunology researchers to its newly formed panel of BiTE(R) antibody advisors. Richard A. Flavell (Yale University, New Haven, Connecticut), Michael J. Keating (MD Anderson Cancer Center, Houston, Texas), Ronald Levy (Stanford University, Stanford, California), Jeffrey V. Ravetch (Rockefeller University, New York, New York), and Anthony W. Tolcher (South Texas Accelerated Research Therapeutics, San Antonio, Texas) will support the ...